ANABOLICRX

The education library

Methyltrienolone: metribolone and R1881

← All education profiles

Educational evidence summary, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review completed. Current Canadian product authorization is not established by this article.

Identity and terminology

Methyltrienolone is also called metribolone and is commonly identified in research as R1881. It must not be confused with trenbolone acetate. Similar names do not make compounds interchangeable, and a research code is not a medicinal authorization.

The material located for this review spans historical clinical citations and laboratory receptor experiments. These sources answer different questions. A molecule used to measure receptor binding in a laboratory is not thereby a suitable treatment for a person.

Historical clinical investigation

A 1966 paper explicitly concerns liver toxicity of this compound. Its bibliographic record was located, but an accessible abstract or full report was not obtained. It is therefore recorded as a safety lead requiring examination, not used to invent an incidence, severity estimate or exposure threshold. [1]

A 1970 report concerns antitumour efficacy and toxicity in advanced breast cancer. Again, the citation was verified but the clinical results were not accessible in the retrieved record. The title establishes that the question was investigated. It does not establish that the treatment was effective, tolerable or preferable to alternatives. [2]

A further historical clinical/metabolic paper was located as a citation lead. Without its methods and results, this review cannot translate its existence into a benefit claim. This is a substantial research limitation, not a minor editorial detail. [3]

What receptor studies can tell us

Research using human prostate and related tissues examines R1881 binding. One investigation indicates that binding in these preparations can have characteristics associated with progesterone receptors as well as the androgen-focused interpretation researchers may initially expect. That matters when interpreting an assay: binding is dependent on the tissue preparation and experimental method. [4]

Other experiments examine receptor binding in rat liver or muscle. They can support laboratory investigation of hormone-receptor biology, but cannot establish human muscle gains, a therapeutic window or a safe exposure. [5,6]

A frequent mistake is to convert a laboratory affinity comparison into a claim that a compound is a certain number of times “better.” Receptor affinity, tissue response, distribution, metabolism and clinical outcomes are different measurements. None can be substituted for the others without validation. This profile therefore avoids internet potency rankings.

Established benefits versus research interest

No established human therapeutic benefit can be confirmed from the accessible material in this summary. That statement is deliberately narrower than claiming that the compound has never been investigated. Historical investigation clearly exists; sufficiently reviewed evidence to support a benefit claim does not yet exist here.

Research utility is also a distinct category of value. A laboratory reagent may help scientists ask questions about receptors without being an appropriate medicinal product. Marketing that blurs those categories can make the evidence sound much stronger than it is.

Safety: what can and cannot be concluded

The liver-toxicity publication is an important unresolved lead. Its title warrants careful review, but it would be inaccurate to quote a numerical toxicity threshold without reading the supporting data. Nor does lack of access justify reassurance.

The retrieved records do not support reliable compound-specific estimates for cardiovascular events, blood-cell changes, fertility impairment, mood effects, kidney injury or long-term cancer outcomes. Those are unanswered questions in this review. A broad androgen-class assessment could add context after sourcing, but should not be presented as if each outcome were measured in a metribolone trial.

Receptor experiments also do not establish that effects in women, men, adolescents or pregnancy are equivalent. No supported clinical use for those groups is established by this review.

Interactions and clinical uncertainty

A verified current human prescribing monograph and validated interaction table were not located. That prevents a responsible list of safe combinations or contraindication exceptions. Product identity and purity are separate unresolved questions for anything sold under a research name; this review does not verify suppliers or products.

The practical educational message is that an absence of dependable interaction data increases uncertainty. It does not mean a compound is compatible with other medicines, alcohol or supplements. Nothing in this summary supports a protective supplement strategy.

Canadian context

Canada’s Schedule IV includes anabolic steroids and their derivatives. This review has not verified a current Canadian human medicinal authorization for methyltrienolone. A laboratory designation, historical cancer paper or overseas listing does not establish authorization for human sale. Classification and product status must be checked separately. [7]

Misconceptions and evidence limitations

R1881 is not simply another name for trenbolone acetate. High receptor affinity is not proof of superior clinical benefit. A historical cancer-study title is not an endorsement. Missing safety information is not favourable safety information.

The accessible record is insufficient for a comprehensive assessment of human benefits and harms. Full historical human reports, current Canadian product records and a clinically reviewed safety assessment are not available in this summary.

References